PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

NCT00328692

Heart Failure, Congestive

COMPLETED PHASE3

Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy

NCT00443690

Heart Failure, Congestive

COMPLETED PHASE3

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614

Heart Failure, Congestive Renal Insufficiency

COMPLETED PHASE2

Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)

NCT00729222

Heart Failure

COMPLETED PHASE2

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

NCT00159627

Heart Failure, Congestive

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Loop diuretics are generally first line therapy in patients hospitalized with acute heart failure syndrome (AHFS). Their use far exceeds that of vasoactive agents. Tubuloglomerular feedback (TGF) is the body's compensatory response to avoid excess fluid loss, and it is activated when elevated sodium concentrations in the distal tubule are detected. TGF is proposed as a contributing factor for the observed diuretic resistance that occurs in patients with heart failure. Higher doses of diuretics are required to overcome the decreased natriuresis and reduced RBF induced by TGF. Ultimately, this action creates a vicious cycle of worsening renal function and diminished diuretic effectiveness.

The primary pharmacologic rationale for the use of KW-3902 in subjects with AHFS is its mechanism of action as an adenosine A1 receptor antagonist. TGF promotes release of adenosine, and adenosine binding to A1 receptors causes vasoconstriction of the afferent arteriole, decreased RBF, and enhanced sodium reabsorption by the proximal tubule. This action results in a decrease in GFR, diminished renal function, and sodium and water retention. Blocking adenosine A1 receptors via a selective adenosine receptor antagonist may limit sodium reabsorption by the proximal tubules without triggering TGF. It promotes vasodilation of the afferent arteriole of the glomerulus, and thus, this strategy offers the potential to overcome diuretic resistance or enhance diuretic responsiveness. It may also reduce the need for increasing diuretic doses that have been associated with worse outcomes.

The objectives of this study are to evaluate the effect of KW-3902IV in addition to intravenous (IV) loop diuretics (such as furosemide) on heart failure signs and symptoms, renal function, and safety in subjects hospitalized with AHFS, volume overload, and renal impairment, and to estimate and compare within-trial medical resource utilization and direct medical costs between patients treated with KW-3902IV versus placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure, Congestive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

Comparator: Placebo (unspecified)

Intervention Type DRUG

rolofylline Pbo 30 mg IV QD; 3 days

2

Group Type EXPERIMENTAL

rolofylline

Intervention Type DRUG

rolofylline 30 mg IV QD; 3 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rolofylline

rolofylline 30 mg IV QD; 3 days

Intervention Type DRUG

Comparator: Placebo (unspecified)

rolofylline Pbo 30 mg IV QD; 3 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

KW-3902IV MK7418

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. History of heart failure of at least 14 days duration for which diuretic therapy has been prescribed
2. Hospitalized for acute heart failure syndrome requiring IV diuretic therapy.
3. Impaired renal function

Exclusion Criteria

1. Acute contrast induced nephropathy
2. Ongoing or planned IV therapy for heart failure with positive inotropic agents, vasopressors, vasodilators, or mechanical support with the exception of IV nitrates
3. BNP \<500 pg/mL or NT-pro-BNP \<2000 pg/mL
4. Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis
5. Severe pulmonary disease
6. Significant stenotic valvular disease
7. Heart transplant recipient or admitted for cardiac transplantation
8. Clinical evidence of acute coronary syndrome in the 2 weeks prior to screening
9. Heart failure due to significant arrhythmias
10. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.
11. Known hepatic impairment
12. Non-cardiac pulmonary edema, including suspected sepsis
13. Allergy to soybean oil or eggs
14. History of seizure
15. Stroke within 2 years
16. History of or current brain tumor of any etiology
17. Brain surgery within 2 years
18. Encephalitis/meningitis within 2 years
19. History of penetrating head trauma
20. Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years
21. History of, or at risk for, alcohol withdrawal seizures
22. Advanced Alzheimer's disease
23. Advanced multiple sclerosis
24. Hgb \<8 g/dL, Hct \<25%, or the need for a blood transfusion
25. Previous exposure to KW-3902

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No